RXRX Recursion Pharmaceuticals
- 10.010
- -0.040-0.40%
- 10.100
- +0.090+0.90%
Recursion Pharmaceuticals News
Form 144 | Recursion Pharmaceuticals(RXRX.US) Director Proposes to Sell 202.93K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Recursion Pharmaceuticals(RXRX.US)$ Director Borgeson Blake intends to sell 20,054 shares of its common stock on May 14, with a total market value of approximately $20
Recursion Pharmaceuticals Shares Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. The Stock May Also Be Moving Amid Continued Strength After the Company Announced on...
Recursion Pharmaceuticals Shares Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. The Stock May Also Be Moving Amid
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining around 20 points on Tuesday.Shares of Sony Group Corporation (NYSE:SONY) rose sharply during Tuesday's session after the company reported better-tha
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Express News | Recursion Announces Completion of Nvidia-Powered Biohive-2, the Largest Supercomputer in Pharmaceutical Industry
Recursion announces completion of Biohive-2 powered by Nvidia, the pharmaceutical industry's largest supercomputer
Recursion announces completion of Biohive-2 powered by Nvidia, the pharmaceutical industry's largest supercomputer
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioScience
The component stock Novavax Pharmaceuticals closed up 47.64%, continuing its 98.66% increase on Friday (May 10); AC Immune rose 42.86%, MacroGenics rose 32.33% Humacyte, Prime Medicine, Beam, Twist Bioscience, Recursion Pharmaceuticals, Coherus BioSciences rose 16.60%-10.00% Novocure also rose 9.17%; Zent
Stocks With More Than 10% Short Interest - Finviz Screener
Recursion Pharmaceuticals Shares Rise 14% on New Nvidia-Powered Supercomputer
Shares of Recursion Pharmaceuticals on Monday climbed after the company said it has completed BioHive-2, its new Nvidia DGX SuperPOD AI supercomputer.
Recursion Pharmaceuticals Shares Are Trading Higher After the Company Announced the Completion of BioHive-2
Recursion Pharmaceuticals Shares Are Trading Higher After the Company Announced the Completion of BioHive-2
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones gaining more than 90 points on Monday.Shares of GameStop Corp. (NYSE:GME) rose sharply during Monday's session amid possible retail investor interest follow
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2,
US stock changes丨Recursion rose more than 3% in the premarket, Q1 revenue exceeded expectations
On May 13 | Recursion (RXRX.US) rose 3.49% to $8.9 in the premarket. The company's Q1 earnings report achieved revenue of US$13.491 million. The previous value was US$12.134 million, and the expected value was US$12.65 million. Needham analyst Jill Blum reaffirmed Recursion's buy rating and maintained a target price of $17.
Recursion Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Recursion Pharmaceuticals CEO Explains How AI Could Make Drug Development Faster and Less Costly
In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs. Recursion Pharmaceuticals is a clinical clinical stage biotech company that received a $50 million investment from Nvidia last summer.
Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ...
Earnings Call Summary | Recursion Pharmaceuticals(RXRX.US) Q1 2024 Earnings Conference
The following is a summary of the Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript:Financial Performance:Recursion Pharmaceuticals ended the first quarter of 2024 with nearly $3
Recursion Pharmaceuticals: A Buy Rating With Growth and Innovation on the Horizon
Needham: Reiterated the Recursion Pharmaceuticals (RXRX.US) rating, adjusted from buy to buy rating, target price $17.00.
Needham: Reiterated the Recursion Pharmaceuticals (RXRX.US) rating, adjusted from buy to buy rating, target price $17.00.
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.
Analysis
Price Target
No Data
